Meeting
2014 ASCO Annual Meeting
A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.
Authors
Paul James Wood
Monash Health, Children's Cancer Centre, Melbourne, Australia
Paul James Wood , Robyn Strong , Grant A. McArthur , Michael Michael , Elizabeth Algar , Andrea Muscat , Lin Rigby , David M. Ashley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
ACTRN12609000978268
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 10061)
DOI
10.1200/jco.2014.32.15_suppl.10061
Abstract #
10061
Poster Bd #
362
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors.
First Author: Suman Malempati
First Author: Stuart Cramer
Poster
2021 ASCO Annual Meeting
Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).
First Author: Jennifer Foster
Poster
2014 ASCO Annual Meeting
A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children’s Oncology Group phase I consortium trial.
First Author: Meredith K. Chuk